Safety, Tolerability and Pharmacokinetics of Liraglutide-depot in Healthy Subjects

Investigation on Safety, Tolerability and Pharmacokinetics of Liraglutide-depot in Healthy Subjects. A Randomised, Double-blind, Placebo-controlled Trial Investigating Subcutaneously Single Dose Escalation of a Sustained Release Formulation of Liraglutide Lysine in Healthy Male Subjects

This trial is conducted in the United States of America (USA). The aim of this trial is to investigate the safety, tolerability and pharmacokinetics (exposure in the body) of liraglutide-depot in healthy subjects.

Inclusion Criteria:

• Body mass index (BMI) between 20 and 35 kg/m^2 (both inclusive) with a body weight of at least 60 kg
• Apart from being obese (BMI above 30 kg/m^2) the subject has to be considered generally healthy

Exclusion Criteria:

• Medical history of, or presence of, cancer, diabetes or any clinically significant cardiovascular, respiratory, metabolic, renal, hepatic, gastrointestinal, endocrine, haematological, dermatological, venereal, neurological, psychiatric diseases or other major disorders
• Clinical or laboratory findings which suggest that the subject cannot be considered generally healthy
• Prescription medicine and non-prescription medicine with few exceptions
• Current and prior history of alcohol or drug abuse
• Current smoking of more than 5 cigarettes per day
• Mental incapacity, language barriers, or unwillingness to comply with the protocol